$755.39
0.12%
NYSE, Sep 12, 10:07 pm CET
ISIN
US5324571083
Symbol
LLY

Eli Lilly and Company Stock price

$755.39
+115.96 18.13% 1M
-66.47 8.09% 6M
-16.61 2.15% YTD
-179.63 19.21% 1Y
+440.17 139.64% 3Y
+606.39 406.97% 5Y
+673.50 822.44% 10Y
+698.44 1,226.41% 20Y
NYSE, Closing price Fri, Sep 12 2025
-0.89 0.12%

Key metrics

Basic
Market capitalization
$714.9b
Enterprise Value
$751.3b
Net debt
$36.4b
Cash
$3.5b
Shares outstanding
946.8m
Valuation (TTM | estimate)
P/E
49.3 | 32.9
P/S
13.4 | 11.5
EV/Sales
14.1 | 12.1
EV/FCF
negative
P/B
39.1
Dividends
DPS
$5.20
Yield 1Y | 5Y
0.7% | 1.0%
Growth 1Y | 5Y
15.0% | 15.1%
Payout 1Y | 3Y
44.4% | 55.9%
Increased
10 Years
Financials (TTM | estimate)
Revenue
$53.3b | $62.3b
EBITDA
$24.3b | $26.2b
EBIT
$22.4b | $25.8b
Net Income
$13.8b | $21.8b
Free Cash Flow
$-50.2m
Growth (TTM | estimate)
Revenue
36.8% | 38.3%
EBITDA
61.8% | 39.5%
EBIT
67.1% | 51.7%
Net Income
88.0% | 105.6%
Free Cash Flow
98.6%
Margin (TTM | estimate)
Gross
82.6%
EBITDA
45.7% | 42.1%
EBIT
42.1%
Net
25.9% | 35.0%
Free Cash Flow
-0.1%
Financial Health
Equity Ratio
18.0%
Return on Equity
74.6%
ROCE
36.3%
ROIC
23.0%
Debt/Equity
2.2
More
EPS
$15.3
FCF per Share
$-0.1
Short interest
1.0%
Employees
47k
Rev per Employee
$960.0k
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Eli Lilly and Company forecast:

26x Buy
74%
9x Hold
26%

Analyst Opinions

35 Analysts have issued a Eli Lilly and Company forecast:

Buy
74%
Hold
26%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
53,258 53,258
37% 37%
100%
- Direct Costs 9,247 9,247
23% 23%
17%
44,012 44,012
40% 40%
83%
- Selling and Administrative Expenses 9,746 9,746
25% 25%
18%
- Research and Development Expense 11,826 11,826
16% 16%
22%
24,332 24,332
62% 62%
46%
- Depreciation and Amortization 1,893 1,893
17% 17%
4%
EBIT (Operating Income) EBIT 22,439 22,439
67% 67%
42%
Net Profit 13,800 13,800
88% 88%
26%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Positive
The Motley Fool
about 2 hours ago
It's not often that something as influential as an effective weight loss drug comes on the market. Eli Lilly (LLY -0.20%) has that product.
Positive
Finbold
about 18 hours ago
As investors position their portfolios for the next year, certain companies stand out for their strong fundamentals and long-term growth drivers.
Neutral
The Motley Fool
one day ago
The past five years have been rocky, to say the least. Investors have dealt with a worldwide pandemic, political tensions, trade wars, actual wars, economic troubles, market crashes, and more.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 47,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today